TC-5619: Completed Phase II enrollment

Targacept completed enrollment of about 125 patients in a double-blind, placebo-controlled, U.S. Phase II trial to evaluate once-daily 1, 5 and 25 mg oral TC-5619 for 12 weeks. AstraZeneca has an opti...